![](/wp-content/uploads/2018/10/xZtU0TtBTIWnZ3eKZxIL.png)
$599
Wegovy Launch Impresses; Guidance Raised; Novo Q2 ’21 Earnings Update
Novo Nordisk hosted its Q2 ’21 earnings call and provided updates across its commercial and pipeline activities, including the ongoing Wegovy and Rybelsus launches and Novo’s intentions to develop and launch an ASCVD or HF product between 2024 and 2028. Of note, the earnings call was previously scheduled for tomorrow (August 5, 2021), but the company curiously moved it up by a day. Below, FENIX provides highlights and insights from the call.